Korro Bio (NASDAQ:KRRO) Given Outperform Rating at William Blair

William Blair restated their outperform rating on shares of Korro Bio (NASDAQ:KRRO) in a report published on Wednesday morning,RTT News reports.

A number of other research analysts have also commented on KRRO. Raymond James began coverage on shares of Korro Bio in a research note on Monday, October 21st. They set a “strong-buy” rating and a $153.00 price objective on the stock. Royal Bank of Canada boosted their target price on shares of Korro Bio from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Monday, October 21st. Finally, HC Wainwright raised their target price on shares of Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $142.17.

Korro Bio Price Performance

NASDAQ KRRO traded down $10.13 on Wednesday, hitting $55.01. The stock had a trading volume of 321,585 shares, compared to its average volume of 69,636. The company’s 50-day moving average is $49.77 and its two-hundred day moving average is $46.92. Korro Bio has a one year low of $30.00 and a one year high of $98.00.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Tuesday, November 12th. The company reported ($2.26) EPS for the quarter, beating the consensus estimate of ($2.55) by $0.29. Analysts forecast that Korro Bio will post -10.02 EPS for the current year.

Insider Activity at Korro Bio

In related news, CFO Vineet Agarwal sold 800 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $70.00, for a total value of $56,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Korro Bio

Several hedge funds have recently made changes to their positions in the stock. MetLife Investment Management LLC increased its position in shares of Korro Bio by 129.0% during the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock worth $122,000 after purchasing an additional 2,050 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Korro Bio by 1,018.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company’s stock worth $164,000 after buying an additional 4,470 shares in the last quarter. Brown Brothers Harriman & Co. increased its position in Korro Bio by 251.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock valued at $95,000 after acquiring an additional 2,041 shares in the last quarter. Quest Partners LLC raised its stake in shares of Korro Bio by 172.1% in the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after acquiring an additional 1,124 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Korro Bio by 71.6% in the 2nd quarter. Point72 Asset Management L.P. now owns 456,085 shares of the company’s stock valued at $15,448,000 after buying an additional 190,259 shares during the last quarter. Institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).